Clinical trials: sponsored by GlaxoSmithKline
Non-alcoholic Fatty Liver Disease
Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH
The purpose of this study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated.
- Trial name
- SKYLINE (NCT06104319)
- Testing
- GSK4532990
- Where
- 14 sites in United States
- Volunteers
- 61 people
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity…
- Trial name
- NCT06411249
- Testing
- Belimumab (GSK1550188)
- Where
- 104 sites in United States, Argentina and 9 more
- Volunteers
- 302 people
- Sponsor
- GlaxoSmithKline
Pneumonia, Bacterial
Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years
This study will evaluate the safety and immune response of a new formulation of pneumococcal vaccine, PnMAPS30plus, in healthy adults aged 50 to 64 years.
- Trial name
- NCT07428759
- Testing
- Pn-MAPS30plus, PCV20
- Where
- 2 sites in Australia
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Primary Myelofibrosis
Extended Access of Momelotinib in Adults With Myelofibrosis
This is an extended-access, long-term safety study for participants with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF) who have not…
- Trial name
- NCT03441113
- Testing
- Momelotinib
- Where
- 112 sites in United States, Australia and 18 more
- Volunteers
- 237 people
- Sponsor
- GlaxoSmithKline
Diarrhoea
A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants
This study evaluates the immune response and safety of a multicomponent, 2-dose Shigella vaccine in preventing shigellosis in African infants.
- Trial name
- NCT06663436
- Testing
- altSonflex1-2-3 Dose A, altSonflex1-2-3 Dose B, altSonflex1-2-3 Dose C
- Where
- Kenya
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
This study is trying to find the right dose of a long-lasting medicine called GSK5784283 for people with asthma that remains uncontrolled even though they are using regular asthma treatments.
- Trial name
- NCT06748053
- Testing
- GSK5784283
- Where
- 137 sites in United States, Bulgaria and 7 more
- Volunteers
- 307 people
- Sponsor
- GlaxoSmithKline
Gastrointestinal Stromal Neoplasms
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
Gastrointestinal Stromal Tumour (GIST) is a soft tissue tumour that develops in the digestive system, most often in the stomach or small intestine.
- Trial name
- NCT07585266
- Testing
- Velzatinib, Imatinib
- Where
- 93 sites in United States, Argentina and 18 more
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline
Neoplasms, Lung
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread.
- Trial name
- NCT07099898
- Testing
- Risvutatug rezetecan (Ris-Rez), Topotecan
- Where
- 144 sites in United States, Argentina and 23 more
- Volunteers
- 420 people
- Sponsor
- GlaxoSmithKline
Cardiovascular Disease
A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events
This study is designed to evaluate whether the adjuvanted recombinant zoster vaccine (RZV) or the adjuvanted respiratory syncytial virus PreFusion protein 3 (RSVPreF3) vaccine can attenuate the progression of coronary plaque in…
- Trial name
- NCT07712380
- Testing
- Adjuvanted RZV vaccine, Adjuvanted RSVPreF3 vaccine
- Volunteers
- 450 people
- Sponsor
- GlaxoSmithKline
Neoplasms
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or…
- Trial name
- NCT05277051
- Testing
- Remzistotug, Dostarlimab, Belrestotug
- Where
- 26 sites in United States, Australia and 7 more
- Volunteers
- 152 people
- Sponsor
- GlaxoSmithKline
Endometrial Carcinoma, Neoplasms, Endometrial
Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer
This is an open-label study, meaning both the researchers and participants will know which treatment is being given. The study has two parts. In Part 1, researchers will identify the most suitable SC dose.
- Trial name
- SAPPHIRE (NCT07860450)
- Testing
- Dostarlimab, Carboplatin and paclitaxel
- Volunteers
- 378 people
- Sponsor
- GlaxoSmithKline
Gastrointestinal Neoplasms
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
This study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or…
- Trial name
- NCT06885034
- Testing
- Risvutatug Rezetecan
- Where
- 85 sites in United States, Australia and 17 more
- Volunteers
- 346 people
- Sponsor
- GlaxoSmithKline
Neoplasms, Endometrial
A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)
The purpose of this study is to see how well mocertatug rezetecan (Mo-Rez) in combination with physician's choice of immunotherapy (dostarlimab or pembrolizumab) works as maintenance therapy in participants with advanced or…
- Trial name
- NCT07684599
- Testing
- Mocertatug rezetecan, Dostarlimab, Pembrolizumab
- Where
- 8 sites in Japan
- Volunteers
- 610 people
- Sponsor
- GlaxoSmithKline
Ovarian Neoplasms
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating ovarian cancer compared to standard treatments.
- Trial name
- NCT07286266
- Testing
- Mocertatug rezetecan, Paclitaxel, Pegylated liposomal doxorubicin (PLD)
- Where
- 22 sites in Australia, Canada and 3 more
- Volunteers
- 450 people
- Sponsor
- GlaxoSmithKline
Nasal Polyps
A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
The aim of this study is to assess the efficacy and safety of GSK5784283 administered as add-on maintenance therapy to participants with CRSwNP.
- Trial name
- PERSISTCRSwNP1 (NCT07782970)
- Testing
- GSK5784283, Standard of Care
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 218 people
- Sponsor
- GlaxoSmithKline
Hepatitis B
Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection
This Phase 1/2a multiple part study is a first time-in-human (FTIH) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single (Part 1) and repeat doses (Part 2) of GSK3965193 in healthy…
- Trial name
- NCT05330455
- Testing
- GSK3965193, Bepirovirsen
- Where
- 14 sites in Canada, France and 4 more
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hypereosinophilic Syndrome
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy.
- Trial name
- DESTINY (NCT05334368)
- Testing
- Depemokimab
- Where
- 60 sites in United States, Argentina and 14 more
- Volunteers
- 110 people
- Sponsor
- GlaxoSmithKline
Cardiovascular Disease
A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors
This study aims to evaluate the effect of the recombinant zoster vaccine (RZV) on the occurrence of clinically important cardiovascular (heart and blood vessel) events, with a focus on major adverse cardiovascular events (MACE)…
- Trial name
- NCT07872046
- Testing
- RZV vaccine
- Volunteers
- 16,390 people
- Sponsor
- GlaxoSmithKline
Nasal Polyps
A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
The aim of this study is to assess the efficacy and safety of GSK5784283 administered as add-on maintenance therapy to participants with CRSwNP.
- Trial name
- PERSISTCRSwNP2 (NCT07782957)
- Testing
- GSK5784283, Standard of Care
- Where
- 4 sites in United States, Australia
- Volunteers
- 218 people
- Sponsor
- GlaxoSmithKline
Healthy Participants, Gastrointestinal Neoplasms
A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on Velzatinib
This study evaluates the effect of moderate and severe renal impairment on the pharmacokinetics (PK) of velzatinib compared with normal renal function.
- Trial name
- NCT07867171
- Testing
- Velzatinib
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.